Covid-19 roundup: BeiGene snags rights to potential antibody treatment; Beefing up manufacturing ops, Regeneron adds 400 jobs at Irish facility
BeiGene snagged exclusive rights to develop and commercialize Singlomics Biopharmaceuticals’ Covid-19 antibodies outside of Greater China, thus expanding the company’s search for a potential treatment.
Under the license agreement, BeiGene can develop, manufacture and commercialize Singlomics’ DXP-593 and DXP-604 in “ex-China territory.” The Beijing-based biotech is set to begin a Phase I study in Australia next month, enrolling up to 30 healthy volunteers. A second multinational Phase I/II study is expected to begin by early October in patients with mild to moderate Covid-19.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.